Envudeucitinib Shows Rapid, Durable Relief Across Scalp, Itch, and Quality of Life in Phase 3
ALMS sits 63% above its 52-week low of $4.275.
Summary
Alumis presented new Phase 3 data at the Fall Clinical Dermatology Conference showing envudeucitinib rapidly and durably improved scalp psoriasis, itch, and quality of life. Over 80% of patients maintained clear or almost clear scalp skin at Week 48, and nearly 80% sustained clinically meaningful itch reduction. These results build on the previously reported 54% PASI 100 rate and reinforce the drug's competitive profile ahead of the planned NDA submission in Q4 2026. The data address high-impact, difficult-to-treat symptoms that differentiate envudeucitinib from existing oral therapies. No new safety signals were observed with long-term exposure.
At the time of this announcement, ALMS was trading at $6.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $930.5M. The 52-week trading range was $4.28 to $31.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.